PsyBio Therapeutics Corp
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PSYBF research report →
Price Chart
About the company
PsyBio Therapeutics Corp. engages in the development of drugs intended for the treatment of mental health challenges and other disorders. The company was founded on October 28, 2009 and is headquartered in Sunrise, FL.
- CEO
- Evan Levine
- IPO
- 2021
- Employees
- 118
- HQ
- Denver, CO, US
Get TickerSpark's AI analysis on PSYBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.27K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.03
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -867.29%
- ROIC
- 328.61%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-50,000+96.8%
- Op Income
- $-4,337,711
- Net Income
- $-4,886,000+55.7%
- EPS
- $-0.04+58.0%
- OCF Growth
- +50.5%
- FCF Growth
- +50.5%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.49
- RSI (14)
- 52
- Avg Volume
- 6.24K
No earnings-call transcripts are available for PSYBF yet.
- Free Float
- 65.8%
- Shares Outstanding
- 127.50M
- Float Shares
- 83.93M
Our PSYBF coverage
Recent articles, reports, and earnings notes.
No research on PSYBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PSYBF report →PsyBio Therapeutics Awarded Approval to Manufacture Biosynthetic Tryptamines at Scale
newsfilecorp.com · Jul 21
PsyBio Therapeutics successfully completes first pre-IND meeting with the FDA
proactiveinvestors.com · Dec 7
PsyBio Therapeutics presents 16 scientific abstracts highlighting its research and development efforts at two scientific conferences
proactiveinvestors.com · Dec 2
PsyBio Therapeutics shares updates on intellectual property and clinical development milestones
proactiveinvestors.com · Nov 30
PsyBio Therapeutics is developing psychoactive compounds which could be a mental health game changer
proactiveinvestors.com · Nov 25
PsyBio Therapeutics announces expansion of its intellectual property portfolio by filing six additional patent applications
proactiveinvestors.com · Nov 19
PsyBio Therapeutics to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th
prnewswire.com · Oct 11
PsyBio Therapeutics successfully demonstrates commercial-scale manufacturing feasibility
proactiveinvestors.com · Oct 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.